In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

BACKGROUND: Imatinib-resistant chronic myeloid leukemia (CML) patients receiving second-line tyrosine kinase inhibitor (TKI) therapy with dasatinib or nilotinib have a higher risk of disease relapse and progression and not infrequently BCR-ABL1 kinase domain (KD) mutations are implicated in therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Soverini, Simona, De Benedittis, Caterina, Castagnetti, Fausto, Gugliotta, Gabriele, Mancini, Manuela, Bavaro, Luana, Machova Polakova, Katerina, Linhartova, Jana, Iurlo, Alessandra, Russo, Domenico, Pane, Fabrizio, Saglio, Giuseppe, Rosti, Gianantonio, Cavo, Michele, Baccarani, Michele, Martinelli, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Technical Advance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970247/
https://www.ncbi.nlm.nih.gov/pubmed/27485109
http://dx.doi.org/10.1186/s12885-016-2635-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970247/
https://www.ncbi.nlm.nih.gov/pubmed/27485109
http://dx.doi.org/10.1186/s12885-016-2635-0

Ejemplares similares